What is Morgan Stanley's price target for IGMS?

Morgan Stanley's latest stated price target for IGM Biosciences Inc. (IGMS) is $2, from its action on Jan 10, 2025.

What is Morgan Stanley's rating on IGMS?

Morgan Stanley rates IGMS Underweight, a bearish rating, as of Jan 10, 2025.

When did Morgan Stanley last change its view on IGMS?

On Jan 10, 2025, Morgan Stanley downgrades to Underweight from Equal-Weight, price target $12 to $2.

Morgan Stanley IGMS price target and rating history

IGM Biosciences Inc. (IGMS) · Health Care

Morgan Stanley rates IGM Biosciences Inc. (IGMS) Underweight with a $2 price target, as of its latest action on Jan 10, 2025. It has published 3 rating actions on IGMS since August 2021, including 0 upgrades and 2 downgrades.

Current rating: Underweight
Price target: $2
Median target, all firms: Too few
Actions on IGMS: 3

Morgan Stanley price target on IGMS

Morgan Stanley price target on IGMS, each point a stated target, August 2021 to January 2025.

Every Morgan Stanley rating on IGMS

Jan 10, 2025
DowngradeMorgan Stanley downgrades to Underweight from Equal-Weight, price target $12 to $2
Dec 14, 2021
DowngradeMorgan Stanley downgrades to Equal-Weight from Overweight, price target $100 to $38
Aug 26, 2021
InitiateMorgan Stanley starts coverage at Overweight, price target $100

Questions about Morgan Stanley and IGMS

What is Morgan Stanley's price target for IGMS?: Morgan Stanley's latest stated price target for IGM Biosciences Inc. (IGMS) is $2, from its action on Jan 10, 2025.
What is Morgan Stanley's rating on IGMS?: Morgan Stanley rates IGMS Underweight, a bearish rating, as of Jan 10, 2025.
When did Morgan Stanley last change its view on IGMS?: On Jan 10, 2025, Morgan Stanley downgrades to Underweight from Equal-Weight, price target $12 to $2.

More IGMS rating histories

All Morgan Stanley ratings IGMS news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.